Literature DB >> 8087420

Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels.

R Kristipati1, L Nádasdi, K Tarczy-Hornoch, K Lau, G P Miljanich, J Ramachandran, J R Bell.   

Abstract

The interaction of two synthetic omega-conopeptides SNX-111 (MVIIA) and SNX-230 (MVIIC) both derived from the marine snail Conus magus, with non-L-type neuronal voltage-sensitive calcium channels (VSCC) in rat brain synaptosomal preparations has been investigated with the aid of well-characterized 125I derivatives of the two peptides. To assess the effects of iodination on the binding characteristics of SNX-111 and SNX-230, the corresponding peptides containing monoiodotyrosine in place of tyrosine, namely, SNX-259 ([127I]SNX-111) and SNX-260 ([127I]SNX-230), respectively, were prepared by solid-phase synthesis. Saturation analysis showed that [125I]SNX-111 and [125I]SNX-230 bound to two distinct classes of high-affinity sites with apparent Kd's of 9 and 11 pM and Bmax's of 0.54 and 2.2 pmol/mg protein, respectively. Kinetic analysis revealed that both peptides exhibited high association rates as well as rapid dissociation rates in contrast to the 125I derivative of the synthetic omega-conopeptide from Conus geographus, GVIA (SNX-124), which binds irreversibly to N-type channels in rat brain synaptosomes. Competition binding experiments with [125I]SNX-111 and [125I]SNX-124 established that both of them bind to the same site, namely, N-type VSCC. The site detected by the binding of [125I]SNX-230 is distinct from N-type VSCC since SNX-111 has very low affinity (K(i) = 135 nM) in competition studies. Recent findings that a novel high-voltage-activated calcium channel in rat cerebellar granule neurons is resistant to blockers of L-, N-, and P-type VSCC but is highly sensitive to SNX-230 suggest that the [125I]SNX-230 binding site may represent this novel type of calcium channel or another, as yet undescribed, VSCC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8087420     DOI: 10.1006/mcne.1994.1026

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  13 in total

1.  Molecular genetics of ecological diversification: duplication and rapid evolution of toxin genes of the venomous gastropod Conus.

Authors:  T F Duda; S R Palumbi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 2.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  SO-3, a new O-superfamily conopeptide derived from Conus striatus, selectively inhibits N-type calcium currents in cultured hippocampal neurons.

Authors:  Lei Wen; Sheng Yang; Haifa Qiao; Zhenwei Liu; Wenxia Zhou; Yongxiang Zhang; Peitang Huang
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 4.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

5.  Preparation and identification of monoclonal antibodies against ω-conotoxin MVIIA.

Authors:  Yanling Yang; Yanling Ma; Heng Li; Shihua Wang; Zhenhong Zhuang
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08

6.  Inhibition of neuromuscular transmission in the myenteric plexus of guinea-pig ileum by omega-conotoxins GVIA, MVIIA, MVIIC and SVIB.

Authors:  S J Hong; Y F Roan; C C Chang
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

7.  Role of Q-type Ca2+ channels in vasopressin secretion from neurohypophysial terminals of the rat.

Authors:  G Wang; G Dayanithi; S Kim; D Hom; L Nadasdi; R Kristipati; J Ramachandran; E L Stuenkel; J J Nordmann; R Newcomb; J R Lemos
Journal:  J Physiol       Date:  1997-07-15       Impact factor: 5.182

Review 8.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

9.  Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain.

Authors:  Howard S Smith; Timothy R Deer
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

10.  Ziconotide: a review of its pharmacology and use in the treatment of pain.

Authors:  Joseph G McGivern
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.